5Ambati J. Age-related macular degeneration and the other doub- le helix[ J]. Invest Ophthalmol Vis Sci,2011,52(5) :2165-2169. 被引量：1
6Rosenfeld P J, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular de- generation[ J]. N Engl J Med,2006,355 ( 14 ) : 1419-1431. 被引量：1
7Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY,et al. Ranibizumab versus verteporfin for neovascular age- related macular degeneration [ J]. N Engl J Med ,2006 ,355 (14) : 1432-1444. 被引量：1
8Singer MA,Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macu- lar dengeration [ J ]. Ophthalmology, 2012,119 ( 6 ) : 1175-1183. 被引量：1
9Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al. The SECURE study: Long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration [ J]. Oph- thalmology ,2013,120( 1 ) : 130-139. 被引量：1
10Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven- year outcomes in ranibizumab-treated patients in ANCHOR, MA- RINA, and HORIZON: A multicenter cohort study (SEVEN-UP) [ J ]. Ophthalmology, 2013,120 ( 11 ) : 2292-2299. 被引量：1
